Compare EML & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | CHRS |
|---|---|---|
| Founded | 1858 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9M | 177.7M |
| IPO Year | 1995 | 2014 |
| Metric | EML | CHRS |
|---|---|---|
| Price | $26.24 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 10.8K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | 185.40 | ★ 472.00 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $248,970,345.00 | N/A |
| Revenue This Year | $19.05 | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | $26.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.61 | $1.09 |
| 52 Week High | $29.91 | $2.62 |
| Indicator | EML | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 49.65 |
| Support Level | $24.53 | $1.33 |
| Resistance Level | $27.16 | $1.46 |
| Average True Range (ATR) | 0.95 | 0.08 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 52.00 | 47.62 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.